We are live on ! Find out more
NRSN icon

NeuroSense Therapeutics
NRSN

7 hedge funds and large institutions have $286K invested in NeuroSense Therapeutics in 2024 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 7 → 7 (0)

0% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 3

8.11% less ownership

Funds ownership: 9.26% → 1.16% (-8.1%)

85% less capital invested

Capital invested by funds: $1.87M → $286K (-$1.59M)

Holders
7
Holders Change
–
Holders Change %
0%
% of All Funds
0.1%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
1
Reduced
–
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
CF
Cantor Fitzgerald
New York
+$75.6K
2
Citadel Advisors
Citadel Advisors
Florida
+$32.6K
3
XT
XTX Topco
Cayman Islands
+$12.7K
4
Commonwealth Equity Services
Commonwealth Equity Services
Massachusetts
+$12K

Top Sellers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
-$1.77M
2
Morgan Stanley
Morgan Stanley
New York
-$1.68K
3
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT)
United Kingdom
-$60

NRSN Hedge Fund Activity: Q3 2024 in Review

7 of the 6,981 institutional investors tracked by Wall St. Rank reported a position in NeuroSense Therapeutics (NRSN) for Q3 2024, worth a combined $286K — down 85% from $1.87M a quarter earlier.

Fund positioning in NRSN was balanced in Q3 2024: 3 funds opened new positions, 3 closed out, 1 added to existing stakes and 0 trimmed.

The largest buyer was Cantor Fitzgerald, opening a new position worth an estimated $75.6K. The largest seller was Armistice Capital, exiting entirely with an estimated $1.77M sold.

  • 7 institutional investors held NeuroSense Therapeutics (NRSN) as of Q3 2024, unchanged from Q2 2024.
  • Funds reported $286K of NeuroSense Therapeutics stock for Q3 2024, down 85% quarter-over-quarter.
  • 3 funds opened new NeuroSense Therapeutics positions in Q3 2024 and 3 closed out, a net change of 0 holders.
  • The largest NeuroSense Therapeutics buyer in Q3 2024 was Cantor Fitzgerald, an estimated $75.6K added.
  • The largest NeuroSense Therapeutics seller in Q3 2024 was Armistice Capital, an estimated $1.77M sold.

Based on aggregated 13F filings for Q3 2024.